Is Kesimpta better than Ocrevus?
Is Kesimpta more effective than Ocrevus?
-
In patients with relapsing forms of multiple sclerosis, Kesimpta is thought to be more effective than Ocrevus in some ways, but no clinical trials have directly compared the two drugs
-
Ocrevus is the only one of the two drugs approved to treat primary progressive multiple sclerosis
Kesimpta (ofatumumab) and Ocrevus (ocrelizumab) are prescription medications used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Ocrevus is also used to treat primary progressive MS in adults.
Kesimpta and Ocrevus have not been compared head-to-head in a clinical trial in patients with relapsing forms of MS, but an indirect comparison indicates that Kesimpta is better than Ocrevus when looking at certain measures of effectiveness.
Researchers have compared the data from two Kesimpta trials (ASCLEPIOS I and ASCLEPIOS II) with data from two Ocruvus trials (OPERA I AND OPERA II) using simulated treatment comparisons.
The researchers found that for the patients with three- and six-month confirmed disability progression, the two drugs appear to be similarly effective. However, treatment with Kesimpta appears to provide a significant improvement in annualized relapse rates (rate ratio: 0.60, 95% CI: 0.43-0.84) compared with Ocrevus, meaning that patients treated with Kesimpta were less likely to experience relapses. Magnetic resonance imaging (MRI) outcomes, which looked at the proportion of patients with gadolinium-enhancing T1 lesions and brain volume change, and NEDA-3 (No Evidence of Disease Activity 3 parameter composite measure) outcomes also significantly favored Kesimpta over Ocrevus.
Kesimpta and Ocrevus are both CD20-directed cytolytic monoclonal antibodies that target B-cells. Exactly how these drugs work is unknown, but it’s thought to be related to their ability to deplete B cells, which reduces the number of relapses patients with MS experience and slows the progression of the disease.
Kesimpta | Ocrevus | |
Company | Novartis Pharmaceuticals | Genentech |
Approved by the FDA | 2009 | 2017 |
Active ingredient | Ofatumumab | Ocrelizumab |
Uses |
Used to treat:
|
Used to treat:
|
Drug class | CD20 monoclonal antibody | CD20 monoclonal antibody |
Route of administration | Subcutaneous (under the skin) injections - Given weekly for three weeks then monthly | Intravenous (infusion) injection - Given twice two weeks apart then six-monthly |
Related Questions
References
- Food and Drug Administration (FDA). Kesimpta Product Label. [Accessed November 3, 2022]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125326s075lbl.pdf.
- Food and Drug Administration (FDA). Ocrevus Product Label. [Accessed November 3, 2022]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761053s029s030lbl.pdf.
- Samjoo IA, Klotz L, Giovannoni G, et al. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2022;66:104031. doi:10.1016/j.msard.2022.104031. https://www.msard-journal.com/article/S2211-0348(22)00539-9/fulltext.
Read next
Related medical questions
- Is Ocrevus a form of chemotherapy?
- How long does an Ocrevus infusion take?
- How does Ocrevus work for MS?
- What types of MS does Ocrevus treat?
- What are the new drugs used for multiple sclerosis (MS)?
- Ocrevus vs Aubagio: How do they compare for MS?
Drug information
Related support groups
- Kesimpta (5 questions, 3 members)
- Ocrevus (12 questions, 12 members)
- Multiple Sclerosis (90 questions, 549 members)